Lumida
/FHTX
⌘K
Foghorn Therapeutics Inc

Foghorn Therapeutics Inc

FHTX
$4.42USD-1.56%-0.07 today

MARKET CAP

262.5M

P/E (TTM)

FWD P/E

DAY RANGE

$4 – $5

52W RANGE

$3
$8

AI Summary

Stalk
TrimMedium

FHTX remains in a prolonged Stage 4 decline under sustained lower highs and lower lows with EMAs sloping downward and acting as resistance. The active Bearish Exhaustion pattern signals sellers losing control and increases the probability of a bottoming attempt or reversal bounce. Despite extreme oversold readings, lack of sustained reversal suggests selling is best deferred. Favor trimming on rallies into declining EMA regions or prior support-turned-resistance zones for structurally aligned execution.

  • Q2 collaboration revenue rose to $16.1M from $7.6M last year.
  • Net loss shrank to $7.2M from $17.9M as R&D expenses fell to $18.5M.
  • Profitability remains weak, failing to convert revenue into profit.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.3M$19.2M$34.2M$22.6M$30.9M
YoY %+206.7%+1357.8%+77.6%-33.8%+36.8%
P / Sales644.5x14.1x7.9x11.5x11.0x
EV / Sales888.5x32.4x16.2x23.6x18.3x
Gross Profit, Adj.$1.3M$19.2M$34.2M$22.6M$30.9M
YoY %+206.7%+1357.8%+77.6%-33.8%+36.8%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit888.5x32.4x16.2x23.6x18.3x
EBITDA, Adj.$-97.5M$-113.8M$-104.5M$-97.2M$-77.1M
YoY %-45.1%-16.7%+8.2%+7.0%+20.6%
Margin %-7392.5%-591.9%-305.8%-429.9%-249.6%
EV / EBITDA-12.0x-5.5x-5.3x-5.5x-7.3x
EBIT$-100.7M$-117.1M$-107.9M$-102.7M$-86.4M
YoY %-47.0%-16.3%+7.9%+4.8%+15.9%
Margin %-7637.1%-609.2%-315.9%-454.3%-279.5%
EV / EBIT-11.6x-5.3x-5.1x-5.2x-6.5x
Net Income$-101.3M$-108.9M$-98.4M$-86.6M$-74.3M
YoY %-47.3%-7.5%+9.6%+12.0%+14.2%
Net Margin-7681.6%-566.3%-288.2%-383.2%-240.3%
EPS (GAAP)-$2.73-$2.62-$2.34-$1.58-$1.18
YoY %+56.2%+4.0%+10.7%+32.5%+25.3%